Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

10,151 total articles

Executive Chairman Ernest Rady Increases Stake in American Assets Trust Through Open Market Purchases

Executive Chairman Ernest Rady Increases Stake in American Assets Trust Through Open Market Purchases

Ernest S. Rady, Executive Chairman of American Assets Trust, Inc. (NYSE:AAT), recently executed several open market purchases totaling approximately $1.7 million in the company's common stock over a three-day period in May 2026. These transactions occurred while AAT shares were trading near their 52-week high. The filing details specific acquisitio…

Director's Purchase of Stock at Entrada Therapeutics Signals Internal Confidence Amid Clinical Milestones

Director's Purchase of Stock at Entrada Therapeutics Signals Internal Confidence Amid Clinical Milestones

A significant transaction involving a director at Entrada Therapeutics, Inc. (NASDAQ:TRDA) suggests internal belief in the company's valuation as the firm prepares to announce key clinical data. Bernhardt G. Zeiher purchased 5,000 shares of common stock on May 20, 2026, at prices ranging from $5.86 to $6.00 per share. This buying activity occurs wh…

Quicklogic CEO Sells Shares Following Stock Option Exercise

Quicklogic CEO Sells Shares Following Stock Option Exercise

The Chief Executive Officer of QUICKLOGIC Corp, Brian C. Faith, recently sold a substantial amount of the company's common stock following the exercise of fully vested options. This transaction occurred as Quicklogic reported its first-quarter 2026 earnings, which showed mixed results, alongside securing a new $2.7 million contract for FPGA design.

Fate Therapeutics CEO Sells Shares; Company Progress Highlighted Amid Clinical Data and Analyst Upgrades

Fate Therapeutics CEO Sells Shares; Company Progress Highlighted Amid Clinical Data and Analyst Upgrades

Fate Therapeutics CEO Bahram Valamehr sold a portion of his company's common stock for $54,482 through automatic sell-to-cover mechanisms. Despite this transaction, the company remains in focus due to recent clinical advancements regarding its FT819 therapy and positive reactions from major financial institutions that have upgraded price targets.

Itron Executive Sells Shares Amid Mixed Performance Signals

Itron Executive Sells Shares Amid Mixed Performance Signals

David Wright, VP, Corporate Controller and Chief Accounting Officer at Itron, Inc., recently sold a block of common stock. This sale occurred while the company reported better-than-expected first-quarter financial results. However, investor sentiment remains mixed due to analyst adjustments regarding future revenue growth.

Insider Activity and Mixed Signals for Itron Amid Q1 Results

Insider Activity and Mixed Signals for Itron Amid Q1 Results

ITRON, INC. (NASDAQ:ITRI) saw one of its Senior Vice Presidents sell shares in May 2026. This transaction occurred against a backdrop of mixed market signals for the company. While Itron recently reported first-quarter earnings and revenue that surpassed analyst expectations, the stock faced pre-market declines, and Roth/MKM lowered its price targe…

Itron's Insider Activity and Mixed Signals Following Q1 Results

Itron's Insider Activity and Mixed Signals Following Q1 Results

Senior Vice President Patrick K disposed of a small number of Itron common shares, which were sold to cover tax withholding related to restricted stock unit vesting. This transaction occurred as the company reported better-than-expected first quarter financial results, but also amid an analyst rating adjustment that lowered the price target due to …

Executive Activity and Mixed Signals Surround Itron Shares

Executive Activity and Mixed Signals Surround Itron Shares

Senior Vice President John F. Marcolini sold a small amount of Itron common stock to cover tax obligations related to restricted unit vesting. This transaction occurred amid mixed market signals for the company: while recent first-quarter financial results exceeded expectations, an analyst firm lowered its price target citing concerns over near-ter…